Soliris and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Soliris (eculizumab), especially for people who are female, 20-29 old, have been taking the drug for 1 - 6 months also take Everolimus, and have Haemolytic uraemic syndrome.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Soliris. It is created by eHealthMe based on reports of 58,774 people who have side effects when taking Soliris from the FDA, and is updated regularly.

What is Soliris?

Soliris has active ingredients of eculizumab. It is often used in paroxysmal nocturnal hemoglobinuria (pnh). eHealthMe is studying from 58,821 Soliris users. Check the latest studies of Soliris.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 591 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

58,774 people reported to have side effects when taking Soliris.
Among them, 22 people (0.04%) have Progressive multifocal leukoencephalopathy.

Could Soliris cause Progressive multifocal leukoencephalopathy?

Among these 22 people:

How long have people been on Soliris when they have Progressive multifocal leukoencephalopathy? *

  • < 1 month: 40 %
  • 1 - 6 months: 60 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Soliris? *

  • female: 72.22 %
  • male: 27.78 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Soliris? *

  • 0-1: 0.0 %
  • 2-9: 5.88 %
  • 10-19: 0.0 %
  • 20-29: 47.06 %
  • 30-39: 0.0 %
  • 40-49: 11.76 %
  • 50-59: 11.76 %
  • 60+: 23.53 %

What are other drugs people take besides Soliris? *

  1. Everolimus: 7 people, 31.82%
  2. Prednisone: 5 people, 22.73%
  3. Amphotericin B: 4 people, 18.18%
  4. Cancidas: 4 people, 18.18%
  5. Acetylsalicylic Acid: 3 people, 13.64%
  6. Rituxan: 3 people, 13.64%
  7. Cellcept: 3 people, 13.64%
  8. Prednisolone: 2 people, 9.09%
  9. Tacrolimus: 2 people, 9.09%
  10. Aspirin: 1 person, 4.55%

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

  1. Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 6 people, 27.27%
  2. Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 5 people, 22.73%
  3. Cytomegalovirus Infection: 5 people, 22.73%
  4. Ischaemic Stroke (stroke; caused by an interruption in the flow of blood to the brain): 5 people, 22.73%
  5. Candida Sepsis (candida in blood stream): 5 people, 22.73%
  6. Acute Kidney Failure: 5 people, 22.73%
  7. Jc Virus Infection: 4 people, 18.18%
  8. Fever: 4 people, 18.18%
  9. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 3 people, 13.64%
  10. High Blood Pressure: 3 people, 13.64%

What are the existing conditions these people have? *

  1. Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 9 people, 40.91%
  2. Lymphangiectasia Intestinal (a disease of the lymphatic vessels of intestine that results in the leakage of protein-rich lymph): 7 people, 31.82%
  3. Transplant Rejection (a transplant material is not worked): 6 people, 27.27%
  4. Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 3 people, 13.64%
  5. Immunodeficiency Disorders: 2 people, 9.09%
  6. Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 1 person, 4.55%
  7. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 4.55%
  8. Haemodynamic Instability (disturbances in the blood movement in our body): 1 person, 4.55%
  9. Constipation: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Soliris and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Soliris:

Progressive multifocal leukoencephalopathy treatments and more:

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Expand to all the drugs that have ingredients of eculizumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Soliris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:


How the study uses the data?

The study uses data from the FDA. It is based on eculizumab (the active ingredients of Soliris) and Soliris (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: